Sort
21,281 grants matching “influenza”
Vaccine development and production
$938,754Sylvain Fleury · University Of Louisiana At Lafayette · U19 · FY2020 · AI
Annual Estimates of Influenza Vaccine Effectiveness: Davidson County, TN
$938,699Marie R Griffin · Vanderbilt University · U18 · FY2008 · IP
Differentiation of Common Respiratory Viruses and SARS
$938,097Mark Aaron Poritz · Biofire Defense, Llc. · U01 · FY2007 · AI
The connection of innate and adaptive anti-cancer immunity
$937,885John Greiner · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
NOX family NADPH oxidases: roles in innate immunity and inflammatory disease
$937,880Thomas Leto · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)
$937,607Walter A. Orenstein · Emory University · N01 · FY2019 · AI
Administrative Core
$937,502Richard J. Whitley · University Of Alabama At Birmingham · U19 · FY2022 · AI
Medicinal Chemistry and Lead Development Core - SR
$937,501Ashish Kumar Pathak · University Of Alabama At Birmingham · U19 · FY2022 · AI
Project 4 - Influenza - UAB
$937,498Richard J. Whitley · University Of Alabama At Birmingham · U19 · FY2022 · AI
Development of novel immunotherapy for influenza virus infection
$937,230Kazue Takahashi · Massachusetts General Hospital · U01 · FY2010 · AI
A PHASE 1/2A CLINICAL TRIAL STUDY TO EVALUATE THE EFFICACY OF MEDI8852 IN THE TREATMENT OF INFLUENZA IN ADULTS CHALLENGED WITH A WILD-TYPE INFLUENZA
$936,714Medimmune Llc · · FY2018 · Department of the Army
X-ray Crystallographic Fragment Screening Core
$936,551Edward V Arnold · Scripps Research Institute, The · U54 · FY2018 · GM
Integrated System for Rapid Detection of Respiratory Pathogens
$936,507Michael J Lochhead · Mbio Diagnostics, Inc. · R01 · FY2013 · AI
Chicago Community-Acquired Pneumonia Consortium
$935,655Richard G Wunderink · Northwestern University At Chicago · U18 · FY2010 · IP
Enabling risk-based testing through characterization of environmentally induced immune dysregulation and susceptibility to the SARS-CoV2 virus and COVID-19
$935,642Florence Burleson · · N01 · FY2022 · ES
PPE Request
$935,415Judith S. Currier · University Of California Los Angeles · S10 · FY2021 · AI
VERMONT IMMUNOBIOL/INFECTIOUS DIS CTR: CORE A: ADMINISTRATIVE/INTELLECTUAL CORE
$935,147Ralph C. Budd · University Of Vermont & St Agric College · P20 · FY2009 · RR
TITER ON CHIP: ALTERNATIVE TO SRID FOR INFLUENZA VACCINE POTENCY DETERMINATION
$935,011Kathy L Rowlen · Indevr, Inc. · R44 · FY2016 · AI
Vaccine and Treatment Evaluation Units: Protocol Development and Implementation for Natural History Challenge Studies for Influenza
$934,569Emmanuel Walter · Duke University · N01 · FY2019 · AI
A Multi-Omics Approach to the Examination of Bacterial Co-pathogens
$934,088David A Rasko · University Of Maryland Baltimore · U19 · FY2023 · AI
Avian Influenza Surveillance in Thailand-Studies at Human-Animal Interface
$934,000Pilaipan Puthavathana · Mahidol University · U19 · FY2007 · CI
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)
$933,971David S Stephens · Emory University · UM1 · FY2021 · AI
Core 1: Facility Management, Maintenance and Operations Core
$933,206Colin S. Duckett · Duke University · UC7 · FY2023 · AI
Tissue factor-dependent coagulation in thrombosis and immune responses
$933,000Nigel Mackman · Univ Of North Carolina Chapel Hill · R35 · FY2023 · HL
Tissue factor-dependent coagulation in thrombosis and immune responses
$933,000Nigel Mackman · Univ Of North Carolina Chapel Hill · R35 · FY2022 · HL